RecoveryInvestigational

AHK-Cu (Copper Tripeptide-3)

Topical

Overview

AHK-Cu is a synthetic copper-binding tripeptide consisting of alanine-histidine-lysine complexed with copper ions. It shares structural and functional similarities with GHK-Cu but contains alanine in place of glycine at the N-terminus.

Mechanism of Action

The peptide is proposed to promote collagen production, angiogenesis, and antioxidant defenses in skin and other tissues..

Research Summary & Key Findings

In vitro studies have shown stimulation of fibroblast proliferation and increased expression of extracellular matrix components. Preclinical dermal models suggest improved wound healing and reduced inflammation with topical application. Clinical evidence is limited to small observational studies in cosmetic formulations, with no published controlled trials in therapeutic indications.

Clinical Status

Investigational

AHK-Cu (Copper Tripeptide-3) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Topical

Related Peptides in Recovery

Find a Provider

Find a verified provider who offers AHK-Cu (Copper Tripeptide-3) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply AHK-Cu (Copper Tripeptide-3).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.